November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

New Liquid Biopsy Approach Shows Promise in Early Breast Cancer Detection and Recurrence Prediction

🧠 AI Analysis 2 min read 👁 9

Researchers have developed an experimental blood test leveraging epigenetic mapping and AI to accurately detect early-stage breast cancer and predict recurrence risks.

New Liquid Biopsy Approach Shows Promise in Early Breast Cancer Detection and Recurrence Prediction🧠AI Analysis

Photo: Medical Xpress

Key points

  • New blood test analyzes epigenetic tags rather than genetic mutations to spot early breast cancer.
  • AI models trained on patient data achieved 95% accuracy in detecting early-stage tumors.
  • The method also outperformed conventional tissue biopsies in predicting patient recurrence risks.

Liquid biopsies have long been pursued as a minimally invasive method to spot cancer early, customize therapies, and foresee relapses. However, traditional approaches often struggle with early detection due to the extreme scarcity of genetic cancer traces in the bloodstream and the risk of false positives. A collaborative team from the Hebrew University of Jerusalem and the Weizmann Institute of Science, alongside clinicians at Kaplan Medical Center, has introduced a novel blood test that targets epigenetic markers rather than purely genetic mutations.

Instead of examining DNA sequences alone, the investigators focused on epigenetic tags—regulatory bookmarks that dictate how genes are expressed within cells. By collaborating with the Mayo Clinic in Florida, the researchers evaluated blood samples from 77 breast cancer patients tracked for over five years and 30 healthy individuals. Utilizing single-molecule microscopy and specialized artificial intelligence algorithms, the system achieved 95 percent accuracy in identifying early-stage breast cancer when tumors were confined and measured two centimeters or smaller.

While these findings are promising, the study remains an early-stage clinical investigation relying on a relatively small cohort. Observational findings of this nature require extensive validation in larger, diverse populations before broad clinical implementation can be considered. The research suggests a potential pathway forward, but limitations in sample size mean it is not yet a diagnostic standard.

What to know: The experimental blood test examines epigenetic tags on nucleosomes released into the blood to spot early breast cancer and estimate recurrence likelihood. Readers should consult qualified healthcare professionals for individual medical guidance and standard screening decisions.

Source Medical Xpress — medicalxpress.com/news/2026-11-experimental-blood-early-breast-cancer.h… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.